Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Nasopharyngeal Carcinoma

ClinicalTrials.gov lists 645 trials for Nasopharyngeal Carcinoma or a narrower condition beneath it. Fujian Cancer Hospital has the most among industry and government lead sponsors, with 18.

MeSH D000077274 Neoplasms Neoplasm C04 C07 C09 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 47 Phase 1/2 Phase 1/2 36 Phase 2 Phase 2 236 Phase 2/3 Phase 2/3 10 Phase 3 Phase 3 129 Phase 4 Phase 4 4 Not applicable Not applicable 71 Observational Observational 111 Phase 1 Phase 1 47 Phase 1/2 Phase 1/2 36 Phase 2 Phase 2 236 Phase 2/3 Phase 2/3 10 Phase 3 Phase 3 129 Phase 4 Phase 4 4 Not applicable Not applicable 71 Observational Observational 111

Trials per phase (log scale)

1 more section with rows

645 of the 645 trials are tagged with Nasopharyngeal Carcinoma itself; the rest are tagged with a narrower condition beneath it.

Get the Nasopharyngeal Carcinoma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Nasopharyngeal Carcinoma trials start? (29)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 65

1994: 1 trials (Phase 3 1) 1998: 1 trials (Observational 1) 1999: 2 trials (Not applicable 2) 2000: 1 trials (Phase 1/2 1) 2001: 3 trials (Observational 1, Phase 2 2) 2003: 4 trials (Observational 2, Phase 3 1, Phase 1/2 1) 2004: 2 trials (Phase 2 1, Phase 1 1) 2005: 3 trials (Observational 3) 2006: 6 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 2 1) 2007: 9 trials (Observational 1, Phase 3 1, Phase 2 4, Phase 1 3) 2008: 9 trials (Observational 1, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 5) 2009: 7 trials (Not applicable 1, Phase 2 5, Phase 1/2 1) 2010: 12 trials (Observational 4, Phase 2 6, Phase 1/2 1, Phase 1 1) 2011: 15 trials (Observational 2, Not applicable 3, Phase 3 2, Phase 2 6, Phase 1 2) 2012: 15 trials (Observational 5, Phase 3 3, Phase 2 5, Phase 1/2 1, Phase 1 1) 2013: 11 trials (Observational 1, Not applicable 1, Phase 3 4, Phase 2/3 1, Phase 2 3, Phase 1 1) 2014: 17 trials (Observational 3, Phase 3 5, Phase 2/3 2, Phase 2 7) 2015: 33 trials (Observational 5, Not applicable 4, Phase 4 1, Phase 3 9, Phase 2 8, Phase 1/2 4, Phase 1 2) 2016: 31 trials (Observational 5, Not applicable 3, Phase 4 1, Phase 3 6, Phase 2 11, Phase 1/2 3, Phase 1 2) 2017: 30 trials (Observational 6, Not applicable 5, Phase 3 5, Phase 2 10, Phase 1/2 3, Phase 1 1) 2018: 38 trials (Observational 5, Not applicable 3, Phase 3 9, Phase 2/3 1, Phase 2 14, Phase 1/2 3, Phase 1 3) 2019: 38 trials (Observational 5, Not applicable 5, Phase 3 4, Phase 2 15, Phase 1/2 2, Phase 1 7) 2020: 47 trials (Observational 7, Not applicable 3, Phase 4 1, Phase 3 10, Phase 2 21, Phase 1 5) 2021: 45 trials (Observational 8, Not applicable 5, Phase 3 8, Phase 2/3 1, Phase 2 19, Phase 1/2 2, Phase 1 2) 2022: 65 trials (Observational 8, Not applicable 13, Phase 3 11, Phase 2/3 2, Phase 2 24, Phase 1/2 1, Phase 1 6) 2023: 49 trials (Observational 10, Not applicable 7, Phase 3 14, Phase 2/3 1, Phase 2 11, Phase 1/2 4, Phase 1 2) 2024: 60 trials (Observational 15, Not applicable 5, Phase 3 13, Phase 2/3 1, Phase 2 22, Phase 1/2 1, Phase 1 3) 2025: 51 trials (Observational 8, Not applicable 5, Phase 3 14, Phase 2 18, Phase 1/2 3, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 38
2025 51
2024 60
2023 49
2022 65
2021 45
2020 47
2019 38
2018 38
2017 30

Showing 10 of 29 earlier years.

Start your 14-day trial Email me all 29 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 49 trials starting in 2026 and about 49 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 122 trials still running at the 2026-10-09 snapshot; registered median of 36 months across 199 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Nasopharyngeal Carcinoma trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 47
Phase 1/2 36
Phase 2 236
Phase 2/3 10
Phase 3 129
Phase 4 4
Not applicable 71
Observational 111
Expanded access 1

How many Nasopharyngeal Carcinoma trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 56
Recruiting 135
Enrolling by invitation 1
Active, not recruiting 51
Completed 130

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Nasopharyngeal Carcinoma trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Fujian Cancer Hospital 18
National Cancer Institute (NCI) 13

Which drugs are being tested for Nasopharyngeal Carcinoma? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
"Capecitabine" 23
TORIPALIMAB 22
Camrelizumab 16
PEMBROLIZUMAB 14
NIVOLUMAB 10

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Cisplatin 1 88
Gemcitabine/Gemzar 43
Intensity-Modulated Radiotherapy 26
Fluorouracile 15
Docetetaxel 15

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Nasopharyngeal Carcinoma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 26 5
Pyrexia 23 5
Anemia 22 4
Pneumonitis 17 5
Vomiting 17 6

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Nasopharyngeal Carcinoma? (322)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial. CA: a cancer journal for clinicians 2025 Yes
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial. JAMA 2025 Yes
Induction chemotherapy plus camrelizumab combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma in non-endemic areas: a phase 2 clinical trial in North China. BMC medicine 2025 Yes
International Consensus Guideline on Delineation of the Clinical Target Volumes at Different Dose Levels for Nasopharyngeal Carcinoma (2024 Version). International journal of radiation oncology, biology, physics 2025 Yes
Bacterial Decolonization With Mupirocin Ointment for Acute Radiation Oral Mucositis Prevention: A Phase 3 Randomized Clinical Trial. JAMA oncology 2025 Yes

Showing 5 of 322 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (81)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Nasopharyngeal carcinoma Annual incidence 1-9 / 1 000 000 United Kingdom GB Exact
Nasopharyngeal carcinoma Annual incidence 1-9 / 1 000 000 United Kingdom GB Exact
Nasopharyngeal carcinoma Annual incidence 1-9 / 1 000 000 United Kingdom GB Unspecified
Nasopharyngeal carcinoma Annual incidence 1-9 / 1 000 000 Belgium Not stated Unspecified
Nasopharyngeal carcinoma Annual incidence 1-9 / 1 000 000 Norway Not stated Exact

Showing 5 of 81 prevalence observations.

Start your 14-day trial Email me the first 50 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Nasopharyngeal carcinoma 150 Exact Orphanet Rare Disease Ontology (ORDO)
Nasopharyngeal carcinoma 150 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages